Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding

Authors: Victoria M. Stevens PharmD, BCCCP, Toby C. Trujillo PharmD, FCCP, FAHA, BCPS, Tyree H. Kiser PharmD, FCCM, FCCP, BCPS, Robert MacLaren PharmD, MPH, FCCM, FCCP, Paul M. Reynolds PharmD, BCCCP, Scott W. Mueller PharmD, BCCCP, FCCM, FCCP

Source: Clinical and Applied Thrombosis/Hemostasis, Vol 27 (2021)

Subject Terms: Diseases of the circulatory (Cardiovascular) system, RC666-701

File Description: electronic resource

Relation: https://doaj.org/toc/1938-2723

Access URL: https://doaj.org/article/aaafdc76bee8415cba4f83955f1243a6

Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center

Authors: Victoria M. Stevens PharmD, Toby Trujillo PharmD, FCCP, FAHA, BCPS-AQ Cardiology, Scott W. Mueller PharmD, BCCCP, FCCM, Robert MacLaren PharmD, FCCM, FCCP, Paul M. Reynolds PharmD, BCCCP, Tyree H. Kiser PharmD, FCCM, FCCP, BCPS

Source: Clinical and Applied Thrombosis/Hemostasis, Vol 25 (2019)

Subject Terms: Diseases of the circulatory (Cardiovascular) system, RC666-701

File Description: electronic resource

Relation: https://doaj.org/toc/1938-2723

Access URL: https://doaj.org/article/872f665bf08e410e97fa7dc0382f2cb3